{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:01:11Z","timestamp":1794988871969,"version":"4.9.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the emergence of microglia-modulating therapies there is an urgent need for reliable biomarkers to evaluate microglial activation states.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using mouse models and human induced pluripotent stem cell-derived microglia (hiMGL), genetically modified to yield the most opposite homeostatic (\n                      <jats:italic>TREM2-<\/jats:italic>\n                      knockout) and disease-associated (\n                      <jats:italic>GRN<\/jats:italic>\n                      -knockout) states, we identified microglia activity-dependent markers. Non-targeted mass spectrometry was used to identify proteomic changes in microglia and cerebrospinal fluid (CSF) of\n                      <jats:italic>Grn<\/jats:italic>\n                      - and\n                      <jats:italic>Trem2<\/jats:italic>\n                      -knockout mice. Additionally, we analyzed the proteome of\n                      <jats:italic>GRN<\/jats:italic>\n                      - and\n                      <jats:italic>TREM2<\/jats:italic>\n                      -knockout hiMGL and their conditioned media. Candidate marker proteins were tested in two independent patient cohorts, the ALLFTD cohort (\n                      <jats:italic>GRN<\/jats:italic>\n                      mutation carriers versus non-carriers), as well as the proteomic data set available from the EMIF-AD MBD study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified proteomic changes between the opposite activation states in mouse microglia and CSF, as well as in hiMGL cell lysates and conditioned media. For further verification, we analyzed the CSF proteome of heterozygous\n                      <jats:italic>GRN<\/jats:italic>\n                      mutation carriers suffering from frontotemporal dementia (FTD). We identified a panel of six proteins (FABP3, MDH1, GDI1, CAPG, CD44, GPNMB) as potential indicators for microglial activation. Moreover, we confirmed three of these proteins (FABP3, GDI1, MDH1) to be significantly elevated in the CSF of Alzheimer\u2019s (AD) patients. Remarkably, each of these markers differentiated amyloid-positive cases with mild cognitive impairment (MCI) from amyloid-negative individuals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The identified candidate proteins reflect microglia activity and may be relevant for monitoring the microglial response in clinical practice and clinical trials modulating microglial activity and amyloid deposition. Moreover, the finding that three of these markers differentiate amyloid-positive from amyloid-negative MCI cases in the AD cohort suggests that these proteins associate with a very early immune response to seeded amyloid. This is consistent with our previous findings in the Dominantly Inherited Alzheimer\u2019s Disease Network (DIAN) cohort, where soluble TREM2 increases as early as 21 years before symptom onset. Moreover, in mouse models for amyloidogenesis, seeding of amyloid is limited by physiologically active microglia further supporting their early protective role. The biological functions of some of our main candidates (FABP3, CD44, GPNMB) also further emphasize that lipid dysmetabolism may be a common feature of neurodegenerative disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-023-00657-w","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T13:01:55Z","timestamp":1695992515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer\u2019s disease patients from controls"],"prefix":"10.1186","volume":"18","author":[{"given":"Ida","family":"Pes\u00e4maa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Darcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan F.","family":"Lichtenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-1627","authenticated-orcid":false,"given":"Christian","family":"Haass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"issue":"21","key":"657_CR1","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1016\/j.neuron.2022.10.015","volume":"110","author":"C Romero-Molina","year":"2022","unstructured":"Romero-Molina C, Garretti F, Andrews SJ, Marcora E, Goate AM. Microglial efferocytosis: diving into the Alzheimer\u2019s disease gene pool. Neuron. 2022;110(21):3513\u201333.","journal-title":"Neuron"},{"issue":"6","key":"657_CR2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cell.2020.05.003","volume":"181","author":"A Deczkowska","year":"2020","unstructured":"Deczkowska A, Weiner A, Amit I. The Physiology, Pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020;181(6):1207\u201317.","journal-title":"Cell"},{"issue":"5","key":"657_CR3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2020.09.029","volume":"108","author":"JW Lewcock","year":"2020","unstructured":"Lewcock JW, Schlepckow K, Di Paolo G, Tahirovic S, Monroe KM, Haass C. Emerging Microglia Biology defines Novel Therapeutic Approaches for Alzheimer\u2019s Disease. Neuron. 2020;108(5):801\u201321.","journal-title":"Neuron"},{"issue":"11","key":"657_CR4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41582-018-0072-1","volume":"14","author":"TK Ulland","year":"2018","unstructured":"Ulland TK, Colonna M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018;14(11):667\u201375.","journal-title":"Nat Rev Neurol"},{"issue":"243","key":"657_CR5","doi-asserted-by":"crossref","first-page":"243ra86","DOI":"10.1126\/scitranslmed.3009093","volume":"6","author":"G Kleinberger","year":"2014","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6(243):243ra86.","journal-title":"Sci Transl Med"},{"issue":"369","key":"657_CR6","doi-asserted-by":"crossref","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","volume":"8","author":"M Suarez-Calvet","year":"2016","unstructured":"Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8(369):369ra178.","journal-title":"Sci Transl Med"},{"issue":"4","key":"657_CR7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(22)00027-8","volume":"21","author":"E Morenas-Rodriguez","year":"2022","unstructured":"Morenas-Rodriguez E, Li Y, Nuscher B, Franzmeier N, Xiong C, Suarez-Calvet M, et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer\u2019s disease: a longitudinal observational study. Lancet Neurol. 2022;21(4):329\u201341.","journal-title":"Lancet Neurol"},{"issue":"2","key":"657_CR8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41593-018-0296-9","volume":"22","author":"S Parhizkar","year":"2019","unstructured":"Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22(2):191\u2013204.","journal-title":"Nat Neurosci"},{"key":"657_CR9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1126\/scitranslmed.aav6221","volume":"11","author":"M Ewers","year":"2019","unstructured":"Ewers M, Franzmeier N, Suarez-Calvet M, Morenas-Rodriguez E, Caballero MAA, Kleinberger G, et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer\u2019s disease. Sci Transl Med. 2019;11:507.","journal-title":"Sci Transl Med"},{"issue":"4","key":"657_CR10","doi-asserted-by":"crossref","first-page":"e11227","DOI":"10.15252\/emmm.201911227","volume":"12","author":"K Schlepckow","year":"2020","unstructured":"Schlepckow K, Monroe KM, Kleinberger G, Cantuti-Castelvetri L, Parhizkar S, Xia D, et al. Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region. EMBO Mol Med. 2020;12(4):e11227.","journal-title":"EMBO Mol Med"},{"key":"657_CR11","doi-asserted-by":"crossref","unstructured":"Gotzl JK, Brendel M, Werner G, Parhizkar S, Sebastian Monasor L, Kleinberger G et al. Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism. EMBO Mol Med. 2019;11(6).","DOI":"10.15252\/emmm.201809711"},{"issue":"7","key":"657_CR12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.15252\/embr.201743922","volume":"18","author":"F Mazaheri","year":"2017","unstructured":"Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 2017;18(7):1186\u201398.","journal-title":"EMBO Rep"},{"issue":"6","key":"657_CR13","first-page":"845","volume":"127","author":"JK G\u00f6tzl","year":"2014","unstructured":"G\u00f6tzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol. 2014;127(6):845\u201360.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"657_CR14","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cell.2016.04.001","volume":"165","author":"H Lui","year":"2016","unstructured":"Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, et al. Progranulin Deficiency Promotes Circuit-Specific synaptic pruning by Microglia via complement activation. Cell. 2016;165(4):921\u201335.","journal-title":"Cell"},{"issue":"1","key":"657_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12014-022-09354-0","volume":"19","author":"S Weiner","year":"2022","unstructured":"Weiner S, Sauer M, Visser PJ, Tijms BM, Vorontsov E, Blennow K, et al. Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer\u2019s disease biomarkers. Clin Proteom. 2022;19(1):13.","journal-title":"Clin Proteom"},{"issue":"2","key":"657_CR16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bbr.2007.07.020","volume":"185","author":"Y Kayasuga","year":"2007","unstructured":"Kayasuga Y, Chiba S, Suzuki M, Kikusui T, Matsuwaki T, Yamanouchi K, et al. Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behav Brain Res. 2007;185(2):110\u20138.","journal-title":"Behav Brain Res"},{"issue":"6","key":"657_CR17","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.4049\/jimmunol.177.6.3520","volume":"177","author":"IR Turnbull","year":"2006","unstructured":"Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177(6):3520\u20134.","journal-title":"J Immunol"},{"key":"657_CR18","doi-asserted-by":"crossref","unstructured":"Lim NK, Moestrup V, Zhang X, Wang WA, Moller A, Huang FD. An Improved Method for Collection of Cerebrospinal Fluid from anesthetized mice. J Vis Exp. 2018(133).","DOI":"10.3791\/56774-v"},{"key":"657_CR19","doi-asserted-by":"crossref","unstructured":"Sebastian Monasor L, Muller SA, Colombo AV, Tanrioever G, Konig J, Roth S et al. Fibrillar abeta triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. Elife. 2020;9.","DOI":"10.7554\/eLife.54083"},{"issue":"4","key":"657_CR20","doi-asserted-by":"crossref","first-page":"e109108","DOI":"10.15252\/embj.2021109108","volume":"41","author":"A Reifschneider","year":"2022","unstructured":"Reifschneider A, Robinson S, van Lengerich B, Gnorich J, Logan T, Heindl S, et al. Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. EMBO J. 2022;41(4):e109108.","journal-title":"EMBO J"},{"issue":"1","key":"657_CR21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13024-018-0297-x","volume":"13","author":"A McQuade","year":"2018","unstructured":"McQuade A, Coburn M, Tu CH, Hasselmann J, Davtyan H, Blurton-Jones M. Development and validation of a simplified method to generate human microglia from pluripotent stem cells. Mol Neurodegener. 2018;13(1):67.","journal-title":"Mol Neurodegener"},{"issue":"12","key":"657_CR22","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1093\/brain\/awaa325","volume":"143","author":"BM Tijms","year":"2020","unstructured":"Tijms BM, Gobom J, Reus L, Jansen I, Hong S, Dobricic V, et al. Pathophysiological subtypes of Alzheimer\u2019s disease based on cerebrospinal fluid proteomics. Brain. 2020;143(12):3776\u201392.","journal-title":"Brain"},{"issue":"12","key":"657_CR23","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1021\/pr900748n","volume":"8","author":"JR Wisniewski","year":"2009","unstructured":"Wisniewski JR, Zougman A, Mann M. Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. J Proteome Res. 2009;8(12):5674\u20138.","journal-title":"J Proteome Res"},{"key":"657_CR24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-1-4939-9164-8_5","volume":"1959","author":"CS Hughes","year":"2019","unstructured":"Hughes CS, Sorensen PH, Morin GB. A standardized and reproducible proteomics protocol for Bottom-Up quantitative analysis of protein samples using SP3 and Mass Spectrometry. Methods Mol Biol. 2019;1959:65\u201387.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"657_CR25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13024-016-0134-z","volume":"11","author":"M Pigoni","year":"2016","unstructured":"Pigoni M, Wanngren J, Kuhn PH, Munro KM, Gunnersen JM, Takeshima H, et al. Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. Mol Neurodegener. 2016;11(1):67.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"657_CR26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1021\/ac026117i","volume":"75","author":"J Rappsilber","year":"2003","unstructured":"Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption\/ionization, nanoelectrospray, and LC\/MS sample pretreatment in proteomics. Anal Chem. 2003;75(3):663\u201370.","journal-title":"Anal Chem"},{"issue":"1","key":"657_CR27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","volume":"14","author":"CS Hughes","year":"2019","unstructured":"Hughes CS, Moggridge S, M\u00fcller T, Sorensen PH, Morin GB, Krijgsveld J. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat Protoc. 2019;14(1):68\u201385.","journal-title":"Nat Protoc"},{"issue":"20","key":"657_CR28","doi-asserted-by":"crossref","first-page":"e105693","DOI":"10.15252\/embj.2020105693","volume":"39","author":"J Tushaus","year":"2020","unstructured":"Tushaus J, Muller SA, Kataka ES, Zaucha J, Sebastian Monasor L, Su M, et al. An optimized quantitative proteomics method establishes the cell type-resolved mouse brain secretome. EMBO J. 2020;39(20):e105693.","journal-title":"EMBO J"},{"issue":"9","key":"657_CR29","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","volume":"13","author":"J Cox","year":"2014","unstructured":"Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics. 2014;13(9):2513\u201326.","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"657_CR30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods. 2020;17(1):41\u20134.","journal-title":"Nat Methods"},{"issue":"9","key":"657_CR31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13(9):731\u201340.","journal-title":"Nat Methods"},{"issue":"9","key":"657_CR32","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1073\/pnas.091062498","volume":"98","author":"VG Tusher","year":"2001","unstructured":"Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98(9):5116\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"657_CR33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","volume":"93","author":"Y Benjamini","year":"2006","unstructured":"Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika. 2006;93(3):491\u2013507.","journal-title":"Biometrika"},{"issue":"5","key":"657_CR34","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.cell.2018.05.003","volume":"173","author":"A Deczkowska","year":"2018","unstructured":"Deczkowska A, Keren-Shaul H, Weiner A, Colonna M, Schwartz M, Amit I. Disease-Associated Microglia: a Universal Immune Sensor of Neurodegeneration. Cell. 2018;173(5):1073\u201381.","journal-title":"Cell"},{"key":"657_CR35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40478-015-0203-5","volume":"3","author":"IR Holtman","year":"2015","unstructured":"Holtman IR, Raj DD, Miller JA, Schaafsma W, Yin Z, Brouwer N, et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis. Acta Neuropathol Commun. 2015;3:31.","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"657_CR36","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique Microglia Type Associated with Restricting Development of Alzheimer\u2019s Disease. Cell. 2017;169(7):1276\u201390e17.","journal-title":"Cell"},{"issue":"3","key":"657_CR37","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. The TREM2-APOE pathway drives the Transcriptional phenotype of dysfunctional microglia in neurodegenerative Diseases. Immunity. 2017;47(3):566\u201381. e9.","journal-title":"Immunity"},{"issue":"9","key":"657_CR38","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1172\/JCI90604","volume":"127","author":"IR Holtman","year":"2017","unstructured":"Holtman IR, Skola D, Glass CK. Transcriptional control of microglia phenotypes in health and disease. J Clin Invest. 2017;127(9):3220\u20139.","journal-title":"J Clin Invest"},{"issue":"10","key":"657_CR39","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41583-018-0057-5","volume":"19","author":"O Butovsky","year":"2018","unstructured":"Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. Nat Rev Neurosci. 2018;19(10):622\u201335.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"657_CR40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/acn3.266","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Hertze J, Zetterberg H, Landqvist Waldo M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2016;3(1):12\u201320.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"657_CR41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000506282","volume":"49","author":"IOC Woollacott","year":"2020","unstructured":"Woollacott IOC, Nicholas JM, Heller C, Foiani MS, Moore KM, Russell LL, et al. Cerebrospinal fluid YKL-40 and chitotriosidase levels in Frontotemporal Dementia Vary by Clinical, genetic and pathological subtype. Dement Geriatr Cogn Disord. 2020;49(1):56\u201376.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"657_CR42","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1038\/s41467-021-23111-1","volume":"12","author":"A Grubman","year":"2021","unstructured":"Grubman A, Choo XY, Chew G, Ouyang JF, Sun G, Croft NP, et al. Transcriptional signature in microglia associated with abeta plaque phagocytosis. Nat Commun. 2021;12(1):3015.","journal-title":"Nat Commun"},{"issue":"1","key":"657_CR43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.immuni.2018.11.004","volume":"50","author":"TR Hammond","year":"2019","unstructured":"Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, et al. Single-cell RNA sequencing of Microglia throughout the mouse lifespan and in the injured brain reveals Complex Cell-State Changes. Immunity. 2019;50(1):253\u201371. e6.","journal-title":"Immunity"},{"issue":"6301","key":"657_CR44","doi-asserted-by":"crossref","first-page":"aad8670","DOI":"10.1126\/science.aad8670","volume":"353","author":"O Matcovitch-Natan","year":"2016","unstructured":"Matcovitch-Natan O, Winter DR, Giladi A, Vargas Aguilar S, Spinrad A, Sarrazin S, et al. Microglia development follows a stepwise program to regulate brain homeostasis. Science. 2016;353(6301):aad8670.","journal-title":"Science"},{"issue":"12","key":"657_CR45","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/s41593-019-0532-y","volume":"22","author":"R Sankowski","year":"2019","unstructured":"Sankowski R, Bottcher C, Masuda T, Geirsdottir L, Sagar, Sindram E, et al. Mapping microglia states in the human brain through the integration of high-dimensional techniques. Nat Neurosci. 2019;22(12):2098\u2013110.","journal-title":"Nat Neurosci"},{"issue":"1","key":"657_CR46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-017-0226-4","volume":"12","author":"F Llorens","year":"2017","unstructured":"Llorens F, Thune K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12(1):83.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"657_CR47","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry. 2010;68(10):903\u201312.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"657_CR48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13195-017-0276-4","volume":"9","author":"D Chiasserini","year":"2017","unstructured":"Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, et al. Differential role of CSF fatty acid binding protein 3, alpha-synuclein, and Alzheimer\u2019s disease core biomarkers in Lewy body disorders and Alzheimer\u2019s dementia. Alzheimers Res Ther. 2017;9(1):52.","journal-title":"Alzheimers Res Ther"},{"key":"657_CR49","doi-asserted-by":"crossref","unstructured":"Dulewicz M, Kulczynska-Przybik A, Slowik A, Borawska R, Mroczko B. Fatty acid binding protein 3 (FABP3) and apolipoprotein E4 (ApoE4) as lipid metabolism-related biomarkers of Alzheimer\u2019s Disease. J Clin Med. 2021;10(14).","DOI":"10.3390\/jcm10143009"},{"key":"657_CR50","doi-asserted-by":"crossref","unstructured":"Higginbotham L, Ping L, Dammer EB, Duong DM, Zhou M, Gearing M et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease. Sci Adv. 2020;6(43).","DOI":"10.1126\/sciadv.aaz9360"},{"issue":"1","key":"657_CR51","doi-asserted-by":"crossref","first-page":"e12377","DOI":"10.1002\/dad2.12377","volume":"14","author":"K Dhiman","year":"2022","unstructured":"Dhiman K, Villemagne VL, Fowler C, Bourgeat P, Li QX, Collins S, et al. Cerebrospinal fluid levels of fatty acid-binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. Alzheimers Dement (Amst). 2022;14(1):e12377.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"657_CR52","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.18632\/aging.101101","volume":"8","author":"M Schmitz","year":"2016","unstructured":"Schmitz M, Llorens F, Pracht A, Thom T, Correia A, Zafar S, et al. Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients. Aging. 2016;8(11):2927\u201335.","journal-title":"Aging"},{"key":"657_CR53","doi-asserted-by":"crossref","unstructured":"Zerr I, Villar-Pique A, Schmitz VE, Poleggi A, Pocchiari M, Sanchez-Valle R et al. Evaluation of human cerebrospinal fluid Malate dehydrogenase 1 as a marker in genetic prion Disease Patients. Biomolecules. 2019;9(12).","DOI":"10.3390\/biom9120800"},{"issue":"1","key":"657_CR54","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00401-019-02093-x","volume":"139","author":"P Oeckl","year":"2020","unstructured":"Oeckl P, Weydt P, Thal DR, Weishaupt JH, Ludolph AC, Otto M. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 2020;139(1):119\u201334.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"657_CR55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-022-00589-x","volume":"17","author":"DW Kim","year":"2022","unstructured":"Kim DW, Tu KJ, Wei A, Lau AJ, Gonzalez-Gil A, Cao T, et al. Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes. Mol Neurodegeneration. 2022;17(1):83.","journal-title":"Mol Neurodegeneration"},{"issue":"6","key":"657_CR56","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","volume":"7","author":"M Furuhashi","year":"2008","unstructured":"Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7(6):489\u2013503.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"657_CR57","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1096\/fasebj.13.8.805","volume":"13","author":"B Binas","year":"1999","unstructured":"Binas B, Danneberg H, McWhir J, Mullins L, Clark AJ. Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization. FASEB J. 1999;13(8):805\u201312.","journal-title":"FASEB J"},{"issue":"2","key":"657_CR58","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuron.2018.12.006","volume":"101","author":"Q Li","year":"2019","unstructured":"Li Q, Cheng Z, Zhou L, Darmanis S, Neff NF, Okamoto J, et al. Developmental heterogeneity of Microglia and Brain myeloid cells revealed by deep single-cell RNA sequencing. Neuron. 2019;101(2):207\u201323e10.","journal-title":"Neuron"},{"issue":"3","key":"657_CR59","first-page":"416","volume":"26","author":"B van Lengerich","year":"2023","unstructured":"van Lengerich B, Zhan L, Xia D, Chan D, Joy D, Park JI, et al. A TREM2-activating antibody with a blood\u2013brain barrier transport vehicle enhances microglial metabolism in Alzheimer\u2019s disease models. Nat Neurosci. 2023;26(3):416\u201329.","journal-title":"Nat Neurosci"},{"key":"657_CR60","doi-asserted-by":"crossref","unstructured":"Munoz Herrera OM, Zivkovic AM. Microglia and cholesterol handling: implications for Alzheimer\u2019s Disease. Biomedicines. 2022;10(12).","DOI":"10.3390\/biomedicines10123105"},{"issue":"18","key":"657_CR61","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1016\/j.cell.2021.08.002","volume":"184","author":"T Logan","year":"2021","unstructured":"Logan T, Simon MJ, Rana A, Cherf GM, Srivastava A, Davis SS, et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184(18):4651\u201368e25.","journal-title":"Cell"},{"key":"657_CR62","doi-asserted-by":"crossref","unstructured":"Zhou C, Shang W, Yin S-K, Shi H, Ying W. Malate-Aspartate Shuttle plays an important role in LPS-Induced Neuroinflammation of mice due to its Effect on STAT3 phosphorylation. Front Mol Biosci. 2021;8.","DOI":"10.3389\/fmolb.2021.655687"},{"issue":"1","key":"657_CR63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40478-018-0612-3","volume":"6","author":"M Huttenrauch","year":"2018","unstructured":"Huttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S, et al. Glycoprotein NMB: a novel Alzheimer\u2019s disease associated marker expressed in a subset of activated microglia. Acta Neuropathol Commun. 2018;6(1):108.","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"657_CR64","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s42255-019-0069-0","volume":"1","author":"H Kuang","year":"2019","unstructured":"Kuang H, Lin JD. GPNMB: expanding the code for liver-fat communication. Nat Metab. 2019;1(5):507\u20138.","journal-title":"Nat Metab"},{"issue":"1","key":"657_CR65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12974-018-1100-1","volume":"15","author":"ML Neal","year":"2018","unstructured":"Neal ML, Boyle AM, Budge KM, Safadi FF, Richardson JR. The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor. J Neuroinflammation. 2018;15(1):73.","journal-title":"J Neuroinflammation"},{"key":"657_CR66","doi-asserted-by":"crossref","first-page":"674739","DOI":"10.3389\/fimmu.2021.674739","volume":"12","author":"M Saade","year":"2021","unstructured":"Saade M, Araujo de Souza G, Scavone C, Kinoshita PF. The role of GPNMB in inflammation. Front Immunol. 2021;12:674739.","journal-title":"Front Immunol"},{"key":"657_CR67","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semcdb.2020.08.001","volume":"112","author":"B Chausse","year":"2021","unstructured":"Chausse B, Kakimoto PA, Kann O. Microglia and lipids: how metabolism controls brain innate immunity. Semin Cell Dev Biol. 2021;112:137\u201344.","journal-title":"Semin Cell Dev Biol"},{"key":"657_CR68","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3389\/fphys.2020.00393","volume":"11","author":"BA Loving","year":"2020","unstructured":"Loving BA, Bruce KD. Lipid and lipoprotein metabolism in Microglia. Front Physiol. 2020;11:393.","journal-title":"Front Physiol"},{"issue":"21","key":"657_CR69","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","volume":"110","author":"RC Paolicelli","year":"2022","unstructured":"Paolicelli RC, Sierra A, Stevens B, Tremblay ME, Aguzzi A, Ajami B, et al. Microglia states and nomenclature: a field at its crossroads. Neuron. 2022;110(21):3458\u201383.","journal-title":"Neuron"},{"issue":"3","key":"657_CR70","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","volume":"51","author":"BW Kunkle","year":"2019","unstructured":"Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414\u201330.","journal-title":"Nat Genet"},{"key":"657_CR71","doi-asserted-by":"crossref","first-page":"134348","DOI":"10.1016\/j.neulet.2019.134348","volume":"708","author":"Q Leyrolle","year":"2019","unstructured":"Leyrolle Q, Laye S, Nadjar A. Direct and indirect effects of lipids on microglia function. Neurosci Lett. 2019;708:134348.","journal-title":"Neurosci Lett"},{"issue":"2","key":"657_CR72","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s12035-017-0422-9","volume":"55","author":"MA Churchward","year":"2018","unstructured":"Churchward MA, Tchir DR, Todd KG. Microglial function during glucose deprivation: inflammatory and neuropsychiatric implications. Mol Neurobiol. 2018;55(2):1477\u201387.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"657_CR73","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cell.2017.07.023","volume":"170","author":"TK Ulland","year":"2017","unstructured":"Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, et al. TREM2 maintains microglial metabolic fitness in Alzheimer\u2019s Disease. Cell. 2017;170(4):649\u201363. e13.","journal-title":"Cell"},{"issue":"6","key":"657_CR74","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer\u2019s disease model. Cell. 2015;160(6):1061\u201371.","journal-title":"Cell"},{"issue":"5","key":"657_CR75","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1172\/JCI77983","volume":"125","author":"PL Poliani","year":"2015","unstructured":"Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, et al. TREM2 sustains microglial expansion during aging and response to demyelination. J Clin Invest. 2015;125(5):2161\u201370.","journal-title":"J Clin Invest"},{"issue":"5","key":"657_CR76","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.neuron.2019.12.007","volume":"105","author":"AA Nugent","year":"2020","unstructured":"Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, et al. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron. 2020;105(5):837\u201354. e9.","journal-title":"Neuron"},{"key":"657_CR77","doi-asserted-by":"crossref","unstructured":"Gouna G, Klose C, Bosch-Queralt M, Liu L, Gokce O, Schifferer M et al. TREM2-dependent lipid droplet biogenesis in phagocytes is required for remyelination. J Exp Med. 2021;218(10).","DOI":"10.1084\/jem.20210227"},{"key":"657_CR78","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/bs.apha.2017.08.004","volume":"82","author":"WC Kreisl","year":"2018","unstructured":"Kreisl WC, Henter ID, Innis RB. Imaging translocator protein as a biomarker of Neuroinflammation in Dementia. Adv Pharmacol. 2018;82:163\u201385.","journal-title":"Adv Pharmacol"},{"issue":"1","key":"657_CR79","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11307-017-1099-1","volume":"20","author":"L Beckers","year":"2018","unstructured":"Beckers L, Ory D, Geric I, Declercq L, Koole M, Kassiou M, et al. Increased expression of translocator protein (TSPO) Marks pro-inflammatory microglia but does not predict neurodegeneration. Mol Imaging Biol. 2018;20(1):94\u2013102.","journal-title":"Mol Imaging Biol"},{"issue":"13","key":"657_CR80","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.15252\/embj.201796516","volume":"36","author":"G Kleinberger","year":"2017","unstructured":"Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, et al. The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J. 2017;36(13):1837\u201353.","journal-title":"EMBO J"},{"key":"657_CR81","doi-asserted-by":"crossref","unstructured":"Pozzo ED, Tremolanti C, Costa B, Giacomelli C, Milenkovic VM, Bader S et al. Microglial pro-inflammatory and anti-inflammatory phenotypes are modulated by translocator protein activation. Int J Mol Sci. 2019;20(18).","DOI":"10.3390\/ijms20184467"},{"issue":"615","key":"657_CR82","doi-asserted-by":"crossref","first-page":"eabe5640","DOI":"10.1126\/scitranslmed.abe5640","volume":"13","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wind K, Wiedemann T, Blume T, Shi Y, Briel N, et al. Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci Transl Med. 2021;13(615):eabe5640.","journal-title":"Sci Transl Med"},{"issue":"6","key":"657_CR83","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.beem.2012.05.002","volume":"26","author":"V Papadopoulos","year":"2012","unstructured":"Papadopoulos V, Miller WL. Role of mitochondria in steroidogenesis. Best Pract Res Clin Endocrinol Metab. 2012;26(6):771\u201390.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"657_CR84","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.conb.2021.10.001","volume":"72","author":"S Amin","year":"2022","unstructured":"Amin S, Carling G, Gan L. New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia. Curr Opin Neurobiol. 2022;72:131\u20139.","journal-title":"Curr Opin Neurobiol"},{"issue":"8","key":"657_CR85","doi-asserted-by":"crossref","first-page":"107689","DOI":"10.1016\/j.celrep.2020.107689","volume":"31","author":"I Weisheit","year":"2020","unstructured":"Weisheit I, Kroeger JA, Malik R, Klimmt J, Crusius D, Dannert A, et al. Detection of deleterious On-Target Effects after HDR-Mediated CRISPR editing. Cell Rep. 2020;31(8):107689.","journal-title":"Cell Rep"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-023-00657-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-023-00657-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-023-00657-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T03:14:14Z","timestamp":1700622854000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-023-00657-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1186\/s13024-023-00657-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.06.15.545187","asserted-by":"object"}]},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]},"assertion":[{"value":"6 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments and handling of mice was performed in compliance with the German animal welfare law and with approval from the Government of Upper Bavaria. CSF was sampled under the animal license: ROB 55.2\u20132532.Vet_02-15-69. All experiments including iPSCs were performed in compliance with all applicable guidelines and regulations. All participants were enrolled in ARTFL (U54NS092089) or LEFFTDS (U01AG045390), together ALLFTD, which is a North American research consortium to study sporadic and familiar FTD. All CSF from the ALLFTD consortium were approved and provided by the National Centralized Repository for Alzheimer\u2019s Disease and Related Dementias (NCRAD).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CH collaborates with Denali Therapeutics. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"70"}}